Clinical Trials · NCT02608853
Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 9,999
- Start date
- Jan 2015
- Locations
- 1 site, United States
- Primary endpoint
- Incidence of all malignant neoplasms